U.S. RESEARCH ROUNDUP-Amyris, APi Group, Rambus
18/05/2023 08:00
May 18 (Reuters) - Wall Street securities analysts revised their ratings and price
targets on several U.S.-listed companies, including Amyris, APi Group and Rambus, on Thursday.
HIGHLIGHTS
* Amyris Inc AMRS.O : Jefferies cuts to hold from buy
* APi Group Corp APG.N : Baird raises to outperform rating
* Rambus Inc RMBS.O : Jefferies raises to buy from hold
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday.
Stock entries are in alphabetical order.
* AIM Immunotech Inc AIM.A : Maxim Group cuts target price to $2 from $3
* Amyris Inc AMRS.O : Jefferies cuts to hold from buy
* Amyris Inc AMRS.O : Jefferies cuts target price to $0.65 from $3.10
* APi Group Corp APG.N : Baird raises target price to $29 from $27
* APi Group Corp APG.N : Baird raises to outperform rating
* Apollo Global Management Inc APO.N : Jefferies cuts target price to $65 from $67
* Applovin Corp APP.O : Wedbush raises target price to $29 from $28
* Ares Management Corp ARES.N : Jefferies raises target price to $94 from $91
* Bionano Genomics Inc BNGO.O : BTIG cuts target price to $2 from $3
* Blackstone Inc BX.N : Jefferies cuts target price to $98 from $101
* Boot Barn Holdings Inc BOOT.N : Jefferies cuts target price to $77 from $88
* Boot Barn Holdings Inc BOOT.N : Piper Sandler cuts target price to $87 from $90
* Bowlero Corp BOWL.N : Jefferies raises target price to $25 from $23
* Carlyle Group Inc CG.O : Jefferies cuts target price to $28 from $29
* Carlyle Group Inc CG.O : Piper Sandler cuts target price to $42 from $46
* Caseys General Stores Inc CASY.O : Jefferies raises target price to $266 from $261
* Chevron Corp CVX.N : Piper Sandler cuts target price to $196 from $203
* Cisco CSCO.O : Credit Suisse cuts target price to $65 from $69
* Cisco CSCO.O : Jefferies cuts target price to $54 from $56
* Cisco CSCO.O : Piper Sandler cuts target price to $51 from $53
* Conocophillips COP.N : Piper Sandler raises target price to $149 from $140
* Copart Inc CPRT.O : Jefferies raises target price to $95 from $91
* Delek US Holdings Inc DK.N : Piper Sandler cuts target price to $27 from $31
* Dynatrace Inc DT.N : Barclays raises target price to $48 from $41
* Dynatrace Inc DT.N : Canaccord Genuity raises target price to $53 from $51
* Dynatrace Inc DT.N : Jefferies raises target price to $50 from $45
* Dynatrace Inc DT.N : JP Morgan raises target price to $53 from $48
* Dynatrace Inc DT.N : Needham raises target price to $56 from $52
* Dynatrace Inc DT.N : Wells Fargo raises target price to $60 from $54
* Exxon Mobil XOM.N : Piper Sandler raises target price to $145 from $134
* Hess Corp HES.N : Piper Sandler raises target price to $168 from $167
* HF Sinclair Corp DINO.N : Piper Sandler cuts target price to $59 from $73
* Ibex Ltd IBEX.O : RBC cuts target price to $27 from $30
* Intercept Pharmaceuticals Inc ICPT.O : Raymond James cuts to market perform from
outperform
* Jack In the Box Inc JACK.O : Jefferies raises target price to $95 from $85
* Jack In the Box Inc JACK.O : Stifel raises target price to $98 from $86
* Juniper Networks Inc JNPR.N : Jefferies cuts target price to $37.50 from $40
* KKR & Co Inc KKR.N : Jefferies cuts target price to $58 from $66
* Kyndryl Holdings Inc KD.N : Susquehanna cuts target price to $14 from $17
* Marathon Petroleum Corp MPC.N : Piper Sandler cuts target price to $138 from $154
* Murphy USA Inc MUSA.N : Jefferies raises target price to $292 from $255
* Newmont NEM.N : CIBC cuts target price to $56 from $63
* Nextgen Healthcare Inc NXGN.O : Piper Sandler cuts target price to $17 from $20
* Nvidia Corp NVDA.O : Oppenheimer raises target price to $350 from $300
* Occidental Petroleum Corp OXY.N : Piper Sandler cuts target price to $61 from $62
* Palo Alto Networks Inc PANW.O : Jefferies raises target price to $230 from $215
* Par Pacific Holdings Inc PARR.N : Piper Sandler cuts target price to $34 from $39
* PBF Energy Inc PBF.N : Piper Sandler cuts target price to $61 from $74
* Phillips 66 PSX.N : Piper Sandler cuts target price to $127 from $141
* Progressive Corp PGR.N : Piper Sandler cuts target price to $135 from $141
* PTC Inc PTC.O : Jefferies raises target price to $67 from $61
* PTC Therapeutics Inc PTCT.O : Credit Suisse raises target price to $55 from $51
* PTC Therapeutics Inc PTCT.O : JP Morgan raises target price to $72 from $64
* Rambus Inc RMBS.O : Jefferies raises to buy from hold
* Rambus Inc RMBS.O : Jefferies raises target price to $65 from $45
* ServiceNow Inc NOW.N : Baird raises target price to $560 from $548
* Starwood Property Trust Inc STWD.N : Raymond James cuts target price to $23.5 from $28
* Synopsys Inc SNPS.O : Wells Fargo raises target price to $420 from $410
* Target Corp TGT.N : D.A. Davidson cuts target price to $193 from $200
* Target Corp TGT.N : JP Morgan raises target price to $182 from $175
* Target Corp TGT.N : RBC cuts target price to $191 from $198
* Target Corp TGT.N : Roth MKM cuts target price to $156 from $158
* TJX Companies Inc TJX.N : Barclays raises target price to $95 from $93
* TPG Inc TPG.O : Jefferies cuts target price to $27 from $32
* Transmedics Group Inc TMDX.O : Canaccord Genuity cuts target price to $86 from $91
* Triumph Group Inc TGI.N : TD Cowen raises target price to $12 from $10
* Valero Energy Corp VLO.N : Piper Sandler cuts target price to $155 from $188
* Williams-Sonoma Inc WSM.N : Jefferies cuts target price to $95 from $97
* X4 Pharmaceuticals Inc XFOR.O : B. Riley raises target price to $4 from $3
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential